Clinical Practice

Use the tool below to view all available Prova Series

Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
CME/CE
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
0.25 credits
- Maria Fleseriu, MD, FACE
0.25 credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CE
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
0.25 credits
- Robert J. Motzer, MD
- Elizabeth R. Plimack, MD, MS, FASCO
0.25 credits
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
CME/CE
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
0.25 credits
- Darren Brenner, MD
0.25 credits
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
CME/CE
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
1.00 credit
- Robert D. Suh, MD
- Lea Azour, MD
- Ashwin Basavaraj, MD
1.00 credit
New Strategies for Individualizing Treatment in DME
New Strategies for Individualizing Treatment in DME
CME/CE
New Strategies for Individualizing Treatment in DME
0.25 credits
- Luis A. Gonzalez, MD, MPH
- Jeremiah Brown Jr., MD, MS, FASRS
0.25 credits
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
CME/CE
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
0.25 credits
- Luis A. Gonzalez, MD, MPH
- Jeremiah Brown Jr., MD, MS, FASRS
0.25 credits
Trial in Progress: Phase 3 MoonRISe-3 Study
Trial in Progress: Phase 3 MoonRISe-3 Study
Oncology and Hematology
Trial in Progress: Phase 3 MoonRISe-3 Study
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
Oncology and Hematology
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
CME/CE
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
0.75 credits
- Vera Bril, MD
- Neelam Goyal, MD
0.75 credits
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
MinuteCE®
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
1.00 program credit
- Vera Bril, MD
- Nicholas J. Silvestri, MD
1.00 program credit
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
MinuteCE®
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
1.00 program credit
- Vera Bril, MD
- Nicholas J. Silvestri, MD
1.00 program credit
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
CME/CE
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
0.75 credits
- Vera Bril, MD
- Jonathan Strober, MD
0.75 credits

Clinical Practice

Popular

Title

Share on ReachMD